Russian Journal of Allergy最新文献

{"title":"Omalizumab in the severe exacerbations of seasonal allergic rhinitis","authors":"K. Pavlova, D. S. Kulichenko, O. Kurbacheva, M. E. Dyneva, N. Ilina","doi":"10.36691/rja1539","DOIUrl":"https://doi.org/10.36691/rja1539","url":null,"abstract":"Background: according to the Federal Clinical Guidelines (FCG), patients with severe persistent allergic rhinitis (AR) and/or severe exacerbation and with the ineffectiveness of the 3rd line pharmacotherapy (antihistamines, leukotriene receptor antagonists, nasal corticosteroids) are recommended to consider the appointment of the omalizumab, but there aren`t practical recommendations on the regimens and duration of the omalizumab therapy in the severe exacerbation of seasonal AR. \u0000Aim: omalizumab additional therapy in patients with severe exacerbation of AR during the pollen season to assess the efficacy and to determine the optimal regimen and duration of treatment. \u0000Materials and methods: this is an open observational uncontrolled prospective single-center study. 10 adult patients with severe exacerbation of seasonal AR due to birch pollen were selected to study. All of them received the 3rd line of therapy according to FCG and had absence or incomplete control: TNSS (Total nasal symptom score) 2. All of them were treated with the omalizumab, dose and regime were prescribed according to instruction take into account the overall IgE level and the patient's weight. Daily symptom diaries and need for rescue medication were evaluated. The primary endpoint was a decrease in the Combined medical and symptom score (CMSS) mean. \u0000Results: the additional omalizumab treatment has improved AR control for all patients and has reduced the rescue medication (TNSS 1.8 [95% CI 1.562.04]; p0.001 and CMSS 2.12 [95% CI 1.742.5]; p0.001 by the end of 1 wk after the first omalizumab injection; TNSS 2.53 [95% CI 2.053.01]; p0.0001 and CMSS 5.22 [95% CI 4.74-5.7]; p0.001 by the end of 4 wk, respectively) . It was noted that the omalizumab effect realization occurs for some time (from 3 to 7 days). Due to short season pollen for birch (1-2 month) the duration of treatment in our study did not exceed 1 month, so we managed to achieve complete control over the symptoms in all patients by the omalizumab with a small multiplicity of injections (1-2). No adverse events were registered during study. \u0000Conclusion: omalizumab additional therapy in patients with severe exacerbation of AR allows to achieving the whole symptoms control. Taking into account the mechanism omalizumab should be administered at least a week before the expected pollen season in patients with severe exacerbation (according to the previous seasons) which did not complete the allergen-specific immunotherapy in a timely manner, and continue therapy for the end of the pollen season.","PeriodicalId":270411,"journal":{"name":"Russian Journal of Allergy","volume":"13 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-05-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"124041682","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Combination therapy of allergic rhinitis: efficacy, safety and impact on quality of life","authors":"K. Pavlova, D. S. Kulichenko, O. Kurbacheva","doi":"10.36691/rja1540","DOIUrl":"https://doi.org/10.36691/rja1540","url":null,"abstract":"Currently, allergic rhinitis is one of the most common allergic diseases, the importance of which is often underestimated by both, doctors and patients themselves, and leads to the severity raising, the physical, professional and social activity decreasing, the sleep disturbance and the quality of life impaired. Despite the modern medicines availability the control level over the symptoms allergic rhinitis remains low in routine clinical practice. Not seeing a quick result of the intranasal glucocorticosteroids use, which have been anti-inflammatory and pathogenetic effects, patients refuse them in favor the fast-acting decongestants, and it can be underline to a chronization and the adverse events. The use of combined intranasal glucocorticosteroids and antihistamines, which have additives effect on the main pathogenesis stages of the allergic inflammation, allows to quickly achieve the control over the most pronounced rhinitis symptoms and can increase the adherence to therapy. This review presents the results of clinical studies and key characteristics of the new nasal spray of the olopatadine and mometasone fixed combination, confirming the high efficacy and good safety profile of olopatadine + mometasone. The olopatadine and mometasone fixed combination using provides a rapid nasal and ocular symptoms resolved in patients with allergic rhinitis, ultimately leading to the quality of life improvement.","PeriodicalId":270411,"journal":{"name":"Russian Journal of Allergy","volume":"118 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-05-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"116620702","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Allergen-specific immunotherapy and real-world evidence","authors":"D. Timoshenko, K. Pavlova, O. Kurbacheva","doi":"10.36691/rja1535","DOIUrl":"https://doi.org/10.36691/rja1535","url":null,"abstract":"Allergen immunotherapy is the main method of IgE-dependent allergic diseases pathogenetic treatment which is widely used in the clinical practice. Despite the fact that there is a large amount of randomized placebo-controlled trials data on the allergen immunotherapy efficacy, a number of questions remain unanswered regarding the efficacy of the allergen immunotherapy in real practice. These questions can be answered using real-world evidence. Conducting real-world evidence studies of the allergen immunotherapy it is necessary to follow a strict methodology and to perform the multivariate analysis of the available data. Using of statistical methods reduces the risk of bias. The REACT study is currently the largest and most comprehensive real-world evidence study of the allergen immunotherapy, which included more than 90,000 patients with allergic rhinitis from Germany. The method of statistical adjustment a propensity score match was used to ensure comparable groups and representative obtained data. The REACT study provided results of fundamental clinical and public health significance: the allergen immunotherapy leads to a sustained and long-term medicine prescribing reduction in patients with allergic rhinitis and asthma, improved control of asthma, and also prevents development of exacerbations and respiratory infections in asthma patients. The REACT study is a good quality real-world evidence study with strict methodology and representative results. Further high quality standard studies of real-world data may not only confirm the randomized trials evidence, but also may become a source of new evidence for the allergen immunotherapy efficacy and safety in real clinical practice.","PeriodicalId":270411,"journal":{"name":"Russian Journal of Allergy","volume":"36 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-05-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"114947851","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The problems of long-term adherence to elimination diets in children with food allergy.","authors":"E. E. Emeliashenkov, S. Makarova, A. Fisenko, N. Murashkin, A. Galimova, O. Ereshko","doi":"10.36691/rja1515","DOIUrl":"https://doi.org/10.36691/rja1515","url":null,"abstract":"In recent years, more and more attention has been paid to the problem of control and (PDF) maintenance of nutritional status in patients with elimination diet for food allergies. The high effectiveness of this treatment method is associated with the risk of nutritional deficiency, impaired physical growth and eating behavior disorders in children due to the possible long-term elimination of important food groups without adequate replacement. This review considers physical growth disorders in children with food allergies due to insufficient intake of micronutrients (vitamins, fatty acids), as well as such behavior disorders as distortion of food and taste preferences and food neophobia. We also discuss the problems of artificial mixture choice in children of the first year of life, correction of the diet in children over one year of age with micronutrient supplementation, as well as the results of studies on the quality of life of both children with elimination diets and people from their families. When prescribing an elimination diet, the doctor must constantly monitor diet and growth indices of the child. It is necessary to take to into account the child's age, his nutritional requirements and possible deficiencies of nutrients while planning the diet, as well as determine the necessary and sufficient diet duration.","PeriodicalId":270411,"journal":{"name":"Russian Journal of Allergy","volume":"87 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-05-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"129282010","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Practical issues of the use of emollients containing filaggrin modulators in the management of patients with atopic dermatitis and xerosis. \u0000 \u0000(Resolution of the Council of Experts)","authors":"E. Fedenko","doi":"10.36691/rja1538","DOIUrl":"https://doi.org/10.36691/rja1538","url":null,"abstract":"Leading experts in the field of dermatovenereology, cosmetology, and allergology took part in the meeting of the expert meeting. The working groups of the Meeting of Experts, after discussion, assessed the contribution of filaggrin deficiency to the pathogenesis of atopic dermatitis and other diseases / conditions accompanied by xerosis and formed recommendations for the use of Admer's emollient, taking into account the role of filaggrin in the development of atopic dermatitis and xerosis. The experts comprehensively considered the choice of basic therapy for atopic dermatitis, xerosis of various etiologies, discussed the possibilities of secondary prevention of AD and developed unified recommendations on the principles of managing such patients and the place of emollients in clinical practice. Proposals were made for further educational, informational and organizational activities aimed at expanding the knowledge of patients and doctors on the problem of using emollients in atopic dermatitis and xerosis of various etiologies. \u0000This article was first published in the Kremlin Medicine Journal, 2022; N1, p. 4654 [1].","PeriodicalId":270411,"journal":{"name":"Russian Journal of Allergy","volume":"27 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"122707423","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rakhim M. Khaitov (06.01.1944 – 11.03.2022)","authors":"Natalia I Ilyna, Georgy O Gudima","doi":"10.36691/rja1530","DOIUrl":"https://doi.org/10.36691/rja1530","url":null,"abstract":"Russian science has suffered a heavy loss. On March 11, 2022, Rakhim Musaevich Khaitov died - Academician of the Russian Academy of Sciences, Doctor of Medical Sciences, Professor, Honored Scientist of the Russian Federation, Scientific Director of the Federal State Budgetary Institution \"SSC Institute of Immunology\" of the Federal Medical and Biological Agency of Russia, Chief Allergist-Immunologist of the Ministry of Health of Russia, member of the Bureau of the Department of Physiology and Fundamental Medicine RAS, Head of the Department of Clinical Allergology and Immunology, Moscow State Medical University named after A.I. Evdokimov of the Ministry of Health of Russia.","PeriodicalId":270411,"journal":{"name":"Russian Journal of Allergy","volume":"-3 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-03-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"124114033","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sublingual allergen-specific therapy in a child with diabetes mellitus","authors":"Irina M. Gayduk, O. Trusova, A. Kamaev, Renata N. Arakelyan","doi":"10.36691/rja1525","DOIUrl":"https://doi.org/10.36691/rja1525","url":null,"abstract":"A description of a clinical case of a pediatric patient (boy, age 12 at the start of observation) with pollen allergy (allergic rhino-conjunctivitis to grass pollen) in combination with insulin-dependent diabetes mellitus is presented. Initiation criteria of allergen-specific immunotherapy (clear seasonal peak of exacerbations, high and concordant data of allergotesting In vivo and In vitro, progredient course of pollinosis clinical signs during years before allergen-specific immunotherapy was started) discussed in case of comorbid patient. Possible risks were analyzed and absence of diabetes mellitus as contraindication for immunotherapy stated. The patient underwent 2 pre-coseasonal courses of sublingual immunotherapy with grass pollen allergens in 2020 and 2021 with a pronounced positive effect. In the second year of treatment, remission of the disease was achieved: almost complete absence of hay fever symptoms in the flowering season of 2021, no progression of the disease, a significant decrease in the need for therapy to relieve symptoms. During the course of therapy, the patient did not show any deterioration in the course of diabetes mellitus, and the daily dose of insulin did not change. The patient is being monitored, and the third course of sublingual immunotherapy with grass pollen allergens is started.","PeriodicalId":270411,"journal":{"name":"Russian Journal of Allergy","volume":"15 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-03-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"131767731","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of anti-IL-5 therapy with mepolizumab for severe bronchial asthma and concomitant inflammatory nasal diseases in real clinical practice","authors":"V. Naumova, Evgeny K. Beltyukov, D. Kiseleva","doi":"10.36691/rja1519","DOIUrl":"https://doi.org/10.36691/rja1519","url":null,"abstract":"BACKGROUND. T2 inflammation underlies non-allergic eosinophilic severe bronchial asthma and chronic rhinosinusitis with nasal polyposis (CRSwNP). Existing targeted anti-IL-5 drugs can improve clinical and functional parameters in patients with a combination of severe asthma and CRSwNP. \u0000AIM: to evaluate mepolizumab efficacy in patients with non-allergic severe asthma and concomitant inflammatory nasal diseases (CIND) in real clinical practice. \u0000MATERIALS AND METHODS. The study was conducted without a control group, by comparing related populations (before-after analysis) and based on the Sverdlovsk regional register of adult patients with severe asthma and CIND. The primary endpoint was asthma control achievement (ACT questionnaire) and decrease in the proportion of patients with uncontrolled severe asthma. The number of asthma exacerbations, emergency calls and hospitalizations, quality of life according to AQLQ questionnaire, peripheral blood eosinophils level and respiratory function (FEV1, FVC, FEV1/FVC) were also assessed. Dynamics of nasal symptoms was assessed using SNOT22 questionnaire and visual analogue scale (VAS). \u0000RESULTS. During 12 months of therapy with mepolizumab, ACT increased from 9 (Q1-Q3: 7-11) to 22 points (Q1-Q3: 21-24) (p0.001). The proportion of patients with uncontrolled asthma decreased from 100% to 10% (p0.001). The number of asthma exacerbations decreased from 3.182.8 per patient per year to 0 (p0.001) and hospitalizations from 0.570.9 per patient per year to 0 (p=0.007). Quality of life according to AQLQ increased from 3.481.05 (95% CI 2.734.24) to 5.590.88 (95% CI 4.966.22) points (p0.001). The number of blood eosinophils decreased from 442 (Q1-Q3: 336-853) to 90 (Q1-Q3: 73-117) cells/l (p0.001). There was increase in FEV1 from 63.9%24.2 (95% CI 46.681.2) to 80.5%18.3 (95% CI 67.493.6) (p=0.015). There was decrease in SNOT22 questionnaire score by 33 points (from 4530 to 2215) (p=0.006) and decrease in VAS score by 5 points (from 8 (Q1-Q3: 5-8) to 3 (Q1-Q3: 3-5)) (p=0.017). \u0000CONCLUSIONS. According to the study results, there were asthma control improvement, asthma exacerbations decrease, quality of life improvement according to AQLQ. Statistically significant peripheral blood eosinophils decrease and respiratory function improvement were also revealed. In patients with CIND, significant improvement in nasal breathing was noted, which was confirmed by scores of SNOT22 and VAS questionnaires.","PeriodicalId":270411,"journal":{"name":"Russian Journal of Allergy","volume":"42 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-03-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"132978841","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Validity of the epidemiology of atopic dermatitis is questionable","authors":"Macharadze D.Sh. Macharadze D.Sh.","doi":"10.36691/rja1508","DOIUrl":"https://doi.org/10.36691/rja1508","url":null,"abstract":"Today, the prevalence rates of atopic dermatitis are very different worldwide. Epidemiological data are primarily influenced by factors such as the lack of a unified approach to the definition of the disease, study design, disease codes, diagnosis, research methods, etc. In addition, it is important what is the severity of atopic dermatitis and the accuracy of the diagnosis. The use of records in electronic records and prescribed prescriptions also indicate insufficiently accurate identification of such patients. It is necessary to clarify the clinical signs of atopic dermatitis, and the codes of diseases, including those misdiagnosed as atopic dermatitis, which directly affects the epidemiology of this disease.","PeriodicalId":270411,"journal":{"name":"Russian Journal of Allergy","volume":"103 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"123056046","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hereditary angioedema with C1-inhibitor deficiency retrospective study of a population of 194 patients","authors":"I. A. Manto, E. Latysheva, D. Timoshenko, Y. Gornostaeva, A. M. Kostinova, Ekaterina N Medunitsyna, Tatiana N. Myasnikova, T. Romanova, N. K. Setdikova, E. Frolov, Olga V. Shubina, T. Latysheva","doi":"10.36691/rja1516","DOIUrl":"https://doi.org/10.36691/rja1516","url":null,"abstract":"ABSTRACT \u0000BACKGROUND: Hereditary angioedema due to C1-inhibitor deficiency is a rare disease caused by deficiency and/or low functional activity of C1-inhibitor. The main symptom of hereditary angioedema is recurrent angioedema in various localizations which can lead to temporary incapacity or even death. \u0000AIMS: To describe a population of patients with hereditary angioedema with C1-inhibitor deficiency from NRC Institute of Immunology FMBA of Russia registry. Another aim of our study was to identify predictors of upper respiratory tract angioedema. \u0000METHODS: 194 patients from NRC Institute of Immunology FMBA of Russia registry from 124 unrelated families with a diagnosis of hereditary angioedema with C1-inhibitor deficiency, confirmed in accordance with accepted diagnostic standards, were enrolled in the retrospective descriptive study. \u0000RESULTS: Overall, 194 patients were included in the analysis (70% female and 30% male). The mean age of patients was 3517 years. 89% of patients had hereditary angioedema type I, 11% of patients had hereditary angioedema type II. The mean age of clinical onset was 119 years. 98% of participants had a history of at least one episode of peripheral angioedema, 86% experienced abdominal attacks, 86% - facial swellings, 49% - laryngeal attacks. The mean diagnostic delay was 17,511,24 years. The older the patient is, the more possible laryngeal attacks (P0.001), facial and neck swellings (P0.001), and abdominal attacks are (P=0.031). There were no significant differences in clinical features between men and women. \u0000CONCLUSIONS: There is a problem of a long diagnostic delay of hereditary angioedema in Russia. We have identified a number of warning criteria of hereditary angioedema as a consequence of the study: the presence of a family history, a combination of recurrent angioedema and abdominal attacks, the onset of angioedema and/or abdominal attacks in early childhood. The existence of such criteria will make it possible to optimize the diagnosis of hereditary angioedema. Moreover, we have identified risk factors of the development of life-threatening angioedema: the patient's age (the older the patient, the higher the risk), as well as a history of angioedema of the face and neck.","PeriodicalId":270411,"journal":{"name":"Russian Journal of Allergy","volume":"97 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"115707497","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}